Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search

New Drug: Tivozanib for advanced clear cell renal cell carcinoma

New Drug: Tivozanib for advanced clear cell renal cell carcinoma
  • Randomized, open-label phase III trial (TIVO-3)
  • RCC with clear cell component with two or three previous treatments
  • Tivozanib 1.5 mg daily (21/28 days) (n=175) vs. sorafenib 400 mg BID (n=175)
  • ORR: 18% vs. 8% (all partial, p=0.017)
  • Median DoR: NR vs. 5.7 mos (HR NS)
  • Median PFS: 6.0 vs. 5.4 mos (HR: 0.62 [0.48-0.80])
  • Median OS: 16.4 vs. 19.7 mos (HR NS)
  • Grade >=3 AEs: hypertension (20% vs. 14%), diarrhea (2% vs. 10%), PPE (1% vs. 10%), hypothyroidism (1% vs. 0), rash (0 vs. 8%)

Lancet Oncol 2020; 21: 95–104

Rini BI, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More